Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
The company plans to add 1700 beds by FY27 through the organic route
Pharma Solutions operates 10 research and development and/or production sites globally
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Subscribe To Our Newsletter & Stay Updated
